Cardiovascular and Metabolism
Cardiovascular disease is the leading cause of death in the world, and half of all cardiovascular deaths occur in Asia. Furthermore, more than 60% of all people with diabetes live in Asia. There is no time to waste in delivering effective treatments to address the increasing burden of these diseases.
At Janssen, we are committed to the prevention and treatment of cardiovascular and metabolic diseases. We aim to develop innovative medicines and a comprehensive care approach to improve the lives of millions who are affected by these diseases.
Diabetes is a major cause of morbidity and mortality in Hong Kong. According to the Centre for Health Protection1 in Hong Kong, diabetes accounted for 1.0% of all deaths in 2018. The prevalence of diabetes2 is estimated at 10% of the population. This number is expected to rise with the ageing population. With proper treatment and management, people living with diabetes can live long and healthy lives without fear of serious complications. DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 receptor agonists represent some of the more recent treatment options for type 2 diabetes.
Janssen has a strong heritage in the area of diabetes and we are committed to improving the lives of people living with type 2 diabetes. Today, we continue to invest in diabetes to discover new treatments that will address some of the most important unmet medical needs for this metabolic disorder.
Centre for Health Protection. Diabetes Mellitus. Updated November 10, 2020. Accessed November 26, 2020. https://web.archive.org/web/20201126094908/https://www.chp.gov.hk/en/healthtopics/content/25/59.html.
Quan J, et al. Diabetes incidence and prevalence in Hong Kong, China during 2006–2014. Diabet Med 2017; 34(7):902-908.